Drug class
Programmed cell death protein 1 (PD-1) immune-checkpoint inhibitor; monoclonal antibody
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of antitumour T-cell activity and restoring immune recognition and killing of tumour cells.
General use cases
- Treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation
- Treatment of locally advanced or metastatic basal cell carcinoma (BCC) after hedgehog pathway inhibitor therapy or when such therapy is inappropriate
- Treatment of selected advanced non-small-cell lung cancer (NSCLC) settings; combination and biomarker criteria depend on current product label and jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
